17 33

Cited 5 times in

Molecular Testing of Lung Cancers

DC FieldValueLanguage
dc.contributor.author심효섭-
dc.date.accessioned2018-07-20T07:51:03Z-
dc.date.available2018-07-20T07:51:03Z-
dc.date.issued2017-
dc.identifier.issn2383-7837-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160591-
dc.description.abstractTargeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories-mutations, gene rearrangements, and amplifications-and propose expanded guidelines on molecular testing of lung cancers.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherThe Korean Society of Pathologists-
dc.relation.isPartOfJournal of Pathology and Translational Medicine-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleMolecular Testing of Lung Cancers-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Pathology-
dc.contributor.googleauthorHyo Sup Shim-
dc.contributor.googleauthorYoon-La Choi-
dc.contributor.googleauthorLucia Kim-
dc.contributor.googleauthorSunhee Chang-
dc.contributor.googleauthorWan-Seop Kim-
dc.contributor.googleauthorMee Sook Roh-
dc.contributor.googleauthorTae-Jung Kim-
dc.contributor.googleauthorSeung Yeon Ha-
dc.contributor.googleauthorJin-Haeng Chung-
dc.contributor.googleauthorSe Jin Jang-
dc.contributor.googleauthorGeon Kook Lee-
dc.contributor.googleauthorThe Korean Cardiopulmonary Pathology Study Group-
dc.contributor.googleauthorand The Korean Molecular Pathology Study Group-
dc.identifier.doi10.4132/jptm.2017.04.10-
dc.contributor.localIdA02219-
dc.relation.journalcodeJ01680-
dc.identifier.eissn2383-7845-
dc.identifier.pmid28427247-
dc.subject.keywordGuideline-
dc.subject.keywordLung neopla는-
dc.subject.keywordMolecular testing-
dc.subject.keywordPrecision medicine-
dc.contributor.alternativeNameShim, Hyo Sup-
dc.contributor.affiliatedAuthorShim, Hyo Sup-
dc.citation.volume51-
dc.citation.number3-
dc.citation.startPage242-
dc.citation.endPage254-
dc.identifier.bibliographicCitationJournal of Pathology and Translational Medicine, Vol.51(3) : 242-254, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.